Immunomedics (IMMU) – Corporate News
-
FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer
-
Gilead Sciences (GILD) Completes Acquisition of Immunomedics (IMMU)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to IMMU Stock Lookup